

At page 1, line 10, please replace "864,866" with --07/864,866--;

At page 1, line 11, please replace "864,807" with --07/864,807--.

In the claims:

Please amend claim 1 as follows:

Sub 1
(Amended) A method for inducing [a population of] CD8⁺ T cells within a population of T cells to proliferate, comprising:

- B2*
- a) activating a population of T cells; and
 - b) stimulating [a CD9 antigen] an accessory molecule on the surface of the T cells with a ligand which binds the [CD9 antigen] accessory molecule, the activating and stimulating steps thereby inducing proliferation of the CD8⁺ T cells within the T cell population.

Please add new claims 45-70 as follows:

B3
45. The method of claim 1, wherein the population of T cells is activated by contacting the T cells with an anti-CD3 antibody.

46. The method of claim 45, wherein anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

47. The method of claim 45, wherein the anti-CD3 antibody is immobilized on a solid phase surface.

48. The method of claim 1, wherein the population of T cells is activated by contacting the T cells with an anti-CD2 antibody.

49. The method of claim 1, wherein the population of T cells is activated by contacting the T cells with a protein kinase C activator and a calcium ionophore.

50. The method of claim 1, wherein the accessory molecule is CD28.

51. The method of claim 1, wherein the ligand is an anti-CD28 antibody.

52. The method of claim 51, wherein the anti-CD28 antibody is an anti-human CD28 monoclonal antibody.

53. The method of claim 1, wherein the accessory molecule is CD9.

54. The method of claim 1, wherein the ligand is an anti-CD9 antibody.

55. The method of claim 54, wherein the anti-CD9 antibody is an anti-human CD9 monoclonal antibody.

56. The method of claim 1, further comprising contacting the T cells with an antigen or portion thereof.

57. The method of claim 1, further comprising
c) monitoring proliferation of the T cells in response to continuing exposure to the ligand; and
d) reactivating and re-stimulating the T cells when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.

58. The method of claim 57, further comprising repeating the steps (c)-(d) to produce a population of T cells increased in number of from about 100- to about 100,000-fold the original T cell population.

59. A method for stimulating CD8⁺ T cells within a population of T cells to proliferate, comprising
a) contacting a population of T cells with
(1) a first agent which stimulates a TCR/CD3 complex-associated signal in the T cells; and
(2) a second agent which stimulates an accessory molecule on the surface of the T cells.

60. The method of claim 59, wherein the first agent is an anti-CD3 antibody.

61. The method of claim 60, wherein anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

62. The method of claim 60, wherein the anti-CD3 antibody is immobilized on a solid phase surface.

63. The method of claim 59, wherein the second agent is an anti-CD28 antibody.

64. The method of claim 63, wherein anti-CD28 antibody is an anti-human CD28 monoclonal antibody.

65. The method of claim 59, wherein the second agent is an anti-CD9 antibody.

66. The method of claim 65, wherein anti-CD9 antibody is an anti-human CD9 monoclonal antibody.

67. The method of claim 59, further comprising:

- b) separating the anti-CD3 antibody from the T cells and second agent;
- c) monitoring proliferation of the T cells in response to continuing exposure to the second agent; and
- d) re-stimulating the T cells with the anti-CD3 antibody and the second agent when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.

68. The method of claim 67, further comprising repeating steps (b)-(d) to produce a population of T cells increased in number of from about 100- to about 100,000-fold the original T cell population.

69. A method for stimulating CD8⁺ T cells within a population of T cells to proliferate, comprising:

- a) contacting a population of T cells with an anti-CD3 antibody, an anti-CD28 antibody, and an anti-CD9 antibody, under conditions appropriate for proliferation of the T cells;
- b) separating the anti-CD3 antibody from the T cells and the anti-CD9 and the anti-CD28 antibody;
- c) monitoring proliferation of the T cells in response to continuing exposure to the anti-CD9 and the anti-CD28 antibody; and
- d) re-stimulating the T cells with the anti-CD3 antibody and the anti-CD9 and the anti-CD28 antibody when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.